Hanmi Pharm. Co., Ltd.
Bear Case (25th pct.)
-53.9% vs price
Base Case (Median)
-48.3% vs price
Bull Case (75th pct.)
-34.0% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $95562.49 | -78.5% | High (40%) |
| PE Comparable | $332585.09 | -25.3% | Medium (25%) |
| Growth Trajectory DCF | $697415.52 | 56.7% | Medium (20%) |
| Graham Number | $182439.30 | -59.0% | Medium (40%) |
| EV/EBITDA | $254499.15 | -42.8% | Medium (20%) |
| EV/FCF | $230140.04 | -48.3% | Medium (20%) |
| Earnings Power Value | $228243.49 | -48.7% | Medium (50%) |
Based on 7 out of 8 methods, 128940.KS appears overvalued at the current price of $445000.00. The base case fair value of $230140.04 implies 48.3% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.